File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence

TitleAssociation of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence
Authors
Issue Date2008
PublisherAmerican Society for Biochemistry and Molecular Biology, Inc.. The Journal's web site is located at http://www.mcponline.org/
Citation
Molecular And Cellular Proteomics, 2008, v. 7 n. 2, p. 315-325 How to Cite?
AbstractHepatocellular carcinoma (HCC) is well known for poor prognosis and short survival because of high recurrence rate even after curative surgery. Today there is no available biomarker or biochemical test to indicate HCC recurrence, and this study aims to identify protein markers that can discriminate postoperative patients with early recurrence (ER), i.e. disease relapsed within the first year. In this study, 103 hepatitis B-related HCC patients were recruited, and 68 of them were used for ER-related biomarker discovery study. Proteomic expression patterns of matched tumor and adjacent non-tumor tissues from these patients plus 16 normal liver tissues were delineated by the two-dimensional gel electrophoresis differential profiling method. Significant protein spots were evaluated by hierarchical clustering analysis. SSP4612 that yielded the highest receiver operating characteristic (ROC) curve value for the ER subgroup of HCC was subsequently identified by tandem mass spectrometry, and the corresponding expression patterns were further confirmed by quantitative PCR, Western blot, and immunohistochemistry. Correlation analysis with clinicopathological data was also examined. Proteomic profiling analysis revealed overexpression of mortalin (gene HSPA9) in HCC when compared with the non-tumor and normal liver tissues (area under the curve (AUC) = 0.821). Furthermore, elevated mortalin level was also detected in the ER subgroup of HCC versus the recurrence-free state (where no cancer recurs for >1 year) (AUC = 0.833, sensitivity = 90.9%, specificity = 71.4%). Metastatic HCC cell lines also exhibited higher levels of mortalin and HSPA9 mRNA. Clinically, mortalin overexpression in HCC was closely associated with advanced tumor stages and venous infiltration, having implications for increased malignancy and aggressive behavior. Mortalin (HSPA9) is associated with HCC metastasis and thus suggested as a tumor marker for predicting early recurrence, which may have immediate clinical applications for cancer surveillance after curative surgery. © 2008 by The American Society for Biochemistry and Molecular Biology, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/72003
ISSN
2015 Impact Factor: 5.912
2015 SCImago Journal Rankings: 3.213
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYi, Xen_HK
dc.contributor.authorLuk, JMen_HK
dc.contributor.authorLee, NPen_HK
dc.contributor.authorPeng, Jen_HK
dc.contributor.authorLeng, Xen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorLau, GKen_HK
dc.contributor.authorBeretta, Len_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T06:37:23Z-
dc.date.available2010-09-06T06:37:23Z-
dc.date.issued2008en_HK
dc.identifier.citationMolecular And Cellular Proteomics, 2008, v. 7 n. 2, p. 315-325en_HK
dc.identifier.issn1535-9476en_HK
dc.identifier.urihttp://hdl.handle.net/10722/72003-
dc.description.abstractHepatocellular carcinoma (HCC) is well known for poor prognosis and short survival because of high recurrence rate even after curative surgery. Today there is no available biomarker or biochemical test to indicate HCC recurrence, and this study aims to identify protein markers that can discriminate postoperative patients with early recurrence (ER), i.e. disease relapsed within the first year. In this study, 103 hepatitis B-related HCC patients were recruited, and 68 of them were used for ER-related biomarker discovery study. Proteomic expression patterns of matched tumor and adjacent non-tumor tissues from these patients plus 16 normal liver tissues were delineated by the two-dimensional gel electrophoresis differential profiling method. Significant protein spots were evaluated by hierarchical clustering analysis. SSP4612 that yielded the highest receiver operating characteristic (ROC) curve value for the ER subgroup of HCC was subsequently identified by tandem mass spectrometry, and the corresponding expression patterns were further confirmed by quantitative PCR, Western blot, and immunohistochemistry. Correlation analysis with clinicopathological data was also examined. Proteomic profiling analysis revealed overexpression of mortalin (gene HSPA9) in HCC when compared with the non-tumor and normal liver tissues (area under the curve (AUC) = 0.821). Furthermore, elevated mortalin level was also detected in the ER subgroup of HCC versus the recurrence-free state (where no cancer recurs for >1 year) (AUC = 0.833, sensitivity = 90.9%, specificity = 71.4%). Metastatic HCC cell lines also exhibited higher levels of mortalin and HSPA9 mRNA. Clinically, mortalin overexpression in HCC was closely associated with advanced tumor stages and venous infiltration, having implications for increased malignancy and aggressive behavior. Mortalin (HSPA9) is associated with HCC metastasis and thus suggested as a tumor marker for predicting early recurrence, which may have immediate clinical applications for cancer surveillance after curative surgery. © 2008 by The American Society for Biochemistry and Molecular Biology, Inc.en_HK
dc.languageengen_HK
dc.publisherAmerican Society for Biochemistry and Molecular Biology, Inc.. The Journal's web site is located at http://www.mcponline.org/en_HK
dc.relation.ispartofMolecular and Cellular Proteomicsen_HK
dc.rightsMolecular and Cellular Proteomics. Copyright © American Society for Biochemistry and Molecular Biology, Inc.en_HK
dc.subject.meshAmino Acid Sequenceen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshCarcinoma, Hepatocellular - genetics - pathology - surgery - virologyen_HK
dc.subject.meshCell Line, Tumoren_HK
dc.subject.meshCluster Analysisen_HK
dc.subject.meshElectrophoresis, Gel, Two-Dimensionalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGene Expression Regulation, Neoplasticen_HK
dc.subject.meshHSP70 Heat-Shock Proteins - chemistry - genetics - metabolismen_HK
dc.subject.meshHepatitis B virusen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLiver Neoplasms - genetics - pathology - surgery - virologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMolecular Sequence Dataen_HK
dc.subject.meshNeoplasm Metastasisen_HK
dc.subject.meshNeoplasm Recurrence, Local - diagnosis - genetics - pathologyen_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshProteome - analysis - chemistryen_HK
dc.subject.meshRNA, Messenger - genetics - metabolismen_HK
dc.subject.meshROC Curveen_HK
dc.subject.meshSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionizationen_HK
dc.subject.meshTumor Markers, Biological - geneticsen_HK
dc.titleAssociation of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrenceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1535-9476&volume=7&issue=2&spage=315&epage=325 (corresponding author)&date=2008&atitle=Association+of+mortalin+(HSPA9)+with+liver+cancer+metastasis+and+prediction+for+early+tumor+recurrenceen_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.emailLee, NP: nikkilee@hku.hken_HK
dc.identifier.emailGuan, XY: xyguan@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.identifier.authorityLee, NP=rp00263en_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1074/mcp.M700116-MCP200en_HK
dc.identifier.pmid17934217-
dc.identifier.scopuseid_2-s2.0-39749200037en_HK
dc.identifier.hkuros141603en_HK
dc.identifier.volume7en_HK
dc.identifier.issue2en_HK
dc.identifier.spage315en_HK
dc.identifier.epage325en_HK
dc.identifier.isiWOS:000253417300009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYi, X=55138104500en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.scopusauthoridLee, NP=7402722690en_HK
dc.identifier.scopusauthoridPeng, J=7401958598en_HK
dc.identifier.scopusauthoridLeng, X=7102492468en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridLau, GK=7102301257en_HK
dc.identifier.scopusauthoridBeretta, L=7005190156en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats